Link Health In-licenses China Rights to Lidocaine Patch

Link Health Group of Guangzhou in-licensed China rights to Lidoderm®, a lidocaine patch product aimed at pain associated with post-herpetic neuralgia. Teikoku Pharma of San Jose , California , a subsidiary of Japan 's Teikoku Seiyaku, developed the product. Link will have China rights to develop, market and distribute Lidoderm, which is described as TPU’s flagship offering, a combination of lidocaine and a soft hydrogel plaster. Lidoderm in approved in the US and EU under the name Versatis®. More details.... Share this with colleagues: // //